HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Contact
2929 N. Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
This onetime AI market darling is now surprisingly undervalued
stocks
Undervalued ASX miner hits production homerun
stocks
Meta earnings: AI-driven improvements in top line fail to impress investors
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.00 | 70.20 | -0.76% |
| CAC 40 | 8,520.88 | 35.24 | 0.42% |
| DAX 40 | 25,640.06 | 28.03 | 0.11% |
| Dow JONES (US) | 52,266.08 | 58.02 | 0.11% |
| FTSE 100 | 10,864.56 | 32.71 | -0.30% |
| HKSE | 25,884.43 | 25.55 | 0.10% |
| NASDAQ | 25,207.73 | 85.55 | 0.34% |
| Nikkei 225 | 64,362.02 | 2,494.59 | 4.03% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,451.08 | 13.45 | 0.18% |
| S&P/ASX 200 | 8,976.80 | 73.10 | -0.81% |
| SSE Composite Index | 3,832.26 | 27.57 | 0.72% |